Myology research highlights

Mutations in GFPT1 (glutamine-fructose-6-phosphate transaminase 1), a gene encoding an enzyme involved in glycosylation of ubiquitous proteins, cause a limb-girdle congenital myasthenic syndrome (LG-CMS) with tubular aggregates (TAs) characterized predominantly by affection of the proximal skeletal muscles and presence of highly organized and remodeled sarcoplasmic tubules in patients’ muscle biopsies. The authors report here the … [Read more]

The efficacy of enzyme replacement therapy (ERT) in patients at an advanced stage of Pompe disease has only been addressed in a few studies. The aim of this study was to assess the long term effects of ERT in a cohort of patients with severe Pompe disease. The authors identified patients from the French Pompe … [Read more]

In myotonic dystrophy type 1, the association between mutation size (CTG expansion) and the severity of cardiac involvement is controversial. A group of french experts supported by AFM-Telethon, involving researchers and clinicians from the Institute, selected 855 patients with myotonic dystrophy type 1 (women, 51%; median age, 37 years), with genetic testing performed at the … [Read more]

  In 2016, the US Food and Drug Administration (FDA) conditionally approved the first phosphorodiamidate morpholino oligomer (morpholino)-based antisense oligonucleotides (AOs) drug, eteplirsen, developed for DMD exon 51 skipping. Eteplirsen remains controversial with insufficient evidence of its therapeutic effect in patients. Here, the authors designed morpholino AOs targeting DMD exon 51 using their recently developed … [Read more]

The 22nd edition of the International Congress of the World Muscle Society was held from October 3rd to 7th, 2017 in Saint-Malo. For the first time ever, the World Muscle Society International Annual Congress (WMS), the annual reference congress on neuromuscular diseases, was held in France, in Saint Malo, from October 3rd to 7th,  2017. … [Read more]

  In the Phase 3 DELOS trial in patients with DMD, idebenone reduced the loss of peak expiratory flow and FVC compared to placebo. Here, post-hoc analyses were conducted to assess whether treatment with idebenone could reduce the risk of patients dropping below clinically meaningful thresholds of FVC% p. The change over 1 year in … [Read more]

  Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common inherited neuropathy, a debilitating disease without known cure. Among patients with CMT1A, disease manifestation, progression and severity are strikingly variable, which poses major challenges for the development of new therapies. Hence, there is a strong need for sensitive outcome measures such as disease and progression … [Read more]

An international collaboration including researchers from the Institute of Myology identified 5 biological markers of the evolution and severity of CMT1A. Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common inherited neuropathy, a debilitating disease without known cure. Among patients with CMT1A, disease manifestation, progression and severity are strikingly variable, which poses major challenges for … [Read more]

Brain function is compromised in myotonic dystrophy type 1 (DM1), but the underlying mechanisms are not fully understood. To gain insight into the cellular and molecular pathways primarily affected, the authors studied a mouse model of DM1 and brains of adult patients. They found pronounced RNA toxicity in the Bergmann glia of the cerebellum, in … [Read more]

Previously, detection of ANO5 protein has been complicated by unspecific antibodies, most of which have not identified the correct protein. The aims of the study were to specify ANO5 protein expression in human skeletal muscle, and to investigate if the ANO5 protein levels are affected by different ANO5 mutations in anoctaminopathy patients. Four different antibodies … [Read more]